- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-1 IPO registration
- 1.1 Form of Underwriting Agreement
- 3.1 Certificate of Amendment to the Certificate of Incorporation of Elevai Labs, Inc., Fka Reactive Medical Labs Inc
- 3.2 Amendment to Second Amended and Restated Certificate of Incorporation of Elevai Labs, Inc
- 3.3 Form of Third Amended and Restated Certificate of Incorporation of Elevai Labs, Inc., to Be Effective Upon the Closing of This Offering
- 3.4 By-laws
- 3.5 Form of Amended and Restated Bylaws of Elevai Labs, Inc., to Be Effective Upon the Closing of This Offering
- 4.1 Form of Common Stock Share Certificate
- 5.1 Opinion of Ortoli Rosenstadt LLP Regarding the Validity of the Securities Being Registered
- 10.1 Stock Transfer Agreement, Dated June 4, 2021, Between BWL Investments LTD. and Reactive Medical Labs Inc
- 10.2 2020 Equity Incentive Plan, As Amended, and Forms of Award Agreements Thereunder
- 10.3 Form of Amended and Restated Consulting Agreement Between Elevai Labs, Inc. and Northstrive Companies Inc
- 10.4 Form of Advisory Agreement Between Elevai Labs, Inc. and Braeden Lichti
- 10.5 Form of Independent Director Offer Letter
- 10.6 Authorized Distributor Agreement, Dated August 30, 2022, Between Elevai Labs, Inc. and Refine USA, LLC
- 10.7 Authorized Distributor and Trademark License Agreement, Dated January 17, 2022, Between Elevai Labs, Inc. and Dermapenworld Pty LTD
- 14.1 Code of Ethics
- 21.1 List of Subsidiaries
- 23.2 Consent of TPS Thayer
- 99.1 Audit Committee Charter
- 99.2 Compensation Committee Charter
- 99.3 Nominating Committee Charter
- EX-FILING FEES Filing Fee Table
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated June 13, 2023, with respect to the consolidated financial statements of Elevai Labs Inc., for the years ended December 31, 2022 and 2021, in this Registration Statement on Form S-1 of Elevai Labs Inc. and the related Prospectus of Elevai Labs Inc. filed with the Securities and Exchange Commission. Our report dated June 13, 2023 contains an explanatory paragraph describing an uncertainty about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/TPS Thayer, LLC
Sugar Land, Texas
September 28, 2023